Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 01)
Doxazosin Tablet
Product Images NDC 50090-3927
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 50090-3927). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Doxazosin Tablets (A308818e E36c 4431 Bf51 274650c38cb0 02)
This appears to be a table showing the results of three studies related to maximum flow and the impact of medication (specifically Doxazosin) on symptom score and rate. The table lists baseline measurements and changes in measurement after taking a placebo or Doxazosin, at different doses and for varying lengths of time. The studies were conducted on patients with hypertension and benign prostatic hyperplasia. The questionnaire used to measure the data is mentioned, as well as the change in endpoint, and the number of patients who were given a dose of 8 mg Doxazosin and had a statistically significant improvement compared to the placebo group.*
Doxazosin Tablets, Usp (A308818e E36c 4431 Bf51 274650c38cb0 03)
Label Image (Lbl500903927)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
